Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy

Zou, Jiahui; He, Jianhua; Wang, Xiaobo; Wang, Yajie; Wu, Chenchen; Shi, Mengya; Jiang, Hu‐Lin; Wu, Zimei; Liu, Jianping; Zhang, Wenli

doi:10.1016/j.jconrel.2022.09.036

Cited by 15 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACE2-CS-PRT@PM also had no significant effects on the indexes of coagulation including prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen level (Figure F–I). In the process of platelet extraction, prostaglandin E1 and EDTA were added to prevent platelet activation; at the same time, platelet membrane was extracted by freeze–thaw method to remove the conglutination particles that may cause coagulation cascade reaction in platelets . Therefore, intravenous injection of ACE2-CS-PRT@PM did not aggregate, lead to thrombosis, or induce coagulation cascade.…”

Section: Resultsmentioning

confidence: 99%

“…In the process of platelet extraction, prostaglandin E1 and EDTA were added to prevent platelet activation; 28 at the same time, platelet membrane was extracted by freeze−thaw method to remove the conglutination particles that may cause coagulation cascade reaction in platelets. 43 Therefore, intravenous injection of ACE2-CS-PRT@PM did not aggregate, lead to thrombosis, or induce coagulation cascade. In addition, ACE2-CS-PRT@PM did not induce the overexpression of ACE2 protein in the liver and kidneys in HPH or normal rats (Figure S4C).…”

Section: T H I S C O N T E N T Imentioning

confidence: 93%

See 1 more Smart Citation

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

Hypoxic pulmonary hypertension (HPH) is characterized by pulmonary vascular sustained constriction and progressive remodeling, which are initiated by hypoxia then with hypoxia-induced additive factors including pulmonary vascular endothelium injury, intrapulmonary angiotension system imbalance, and inflammation. Now HPH is still an intractable disease lacking effective treatments. Gene therapy has a massive potential for HPH but is hindered by a lack of efficient targeted delivery and hypoxia-responsive regulation systems for transgenes. Herein, we constructed the hypoxia-responsive plasmid of angiotensin-converting enzyme 2 (ACE2) with endothelial-specific promoter Tie2 and a hypoxia response element and next prepared its biomimetic nanoparticle delivery system, named ACE2-CS-PRT@PM, by encapsulating the plasmid of ACE2 with protamine and chondroitin sulfate as the core then coated it with a platelet membrane as a shell for targeting the injured pulmonary vascular endothelium. ACE2-CS-PRT@PM has a 194.3 nm diameter with a platelet membrane-coating core–shell structure and a negatively charged surface, and it exhibits higher delivery efficiency targeting to pulmonary vascular endothelium and hypoxia-responsive overexpression of ACE2 in endothelial cells in a hypoxia environment. In vitro, ACE2-CS-PRT@PM significantly inhibited the hypoxia-induced proliferation of pulmonary smooth muscle cells. In vivo, ACE2-CS-PRT@PM potently ameliorated the hemodynamic dysfunction and morphological abnormality and largely reversed HPH via inhibiting the hypoxic proliferation of pulmonary artery smooth muscle cells, reducing pulmonary vascular remodeling, restoring balance to the intrapulmonary angiotension system, and improving the inflammatory microenvironment without any detectable toxicity. Therefore, ACE2-CS-PRT@PM is promising for the targeted gene therapy of HPH.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: T H I S C O N T E N T Imentioning

confidence: 93%

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[45] Therefore, the construction of a sizeadapting drug carrier according to the specificity of TME is a promising strategy. Recently, Zou et al [46] developed a micronanoscale switchable DDS that can regulate the carrier size in delivery. Hollow gold nanoparticles are coated with platelet membrane micro-scale carrier, improving the targeting efficiency of the tumor.…”

Section: Dynamic Assembly/disassembly-controlled Drug Releasementioning

confidence: 99%

“…Recently, Zou et al. [ 46 ] developed a micro‐nanoscale switchable DDS that can regulate the carrier size in delivery. Hollow gold nanoparticles are coated with platelet membrane micro‐scale carrier, improving the targeting efficiency of the tumor.…”

Section: Interactions and Responsive Release Mechanismmentioning

confidence: 99%

“…Organic and inorganic hybrid hollow silica with ultra-thin shells can also achieve deformation through the swelling pH polypeptide polymer Not mentioned [44] pH PG@HGNs Not mentioned [46] Ultrasound liposomal nanodroplet Hydrophobic [23] Solvent activation pH BG-HA@CS Electrostatic interaction and hydrogen bond [49] pH Ce Physical adsorption [50] Not mentioned PMO Hydrophobic van der Waals forces [47] Chemical ond pH G-AuNPs-PEG Hydrazone bonds [34] pH Fe 3 O 4 @mSiO 2 @P2 Hydrophilic interaction hydrogen bond [52] pH MSN Amide bond physical adsorption [53] pH strategy of organic groups. Teng et al [47] fabricated hollow periodic mesoporous organosilicon (PMO) equipped with tunable shell thickness and low Young's modulus, thereby showing a swellability property in organic solvents.…”

Section: Solvent Activation-controlled Drug Releasementioning

confidence: 99%

See 1 more Smart Citation

Response and Regulation of the Microenvironment Based on Hollow Structured Drug Delivery Systems

Zhao

Wei

Xiong

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Hollow structured materials with easily modifiable surfaces and enclosed interior spaces have emerged as the most promising candidates in drug delivery systems (DDS). With various functional components and inspiring cavities for creative reinvention, the response and regulation of the external and internal microenvironment of hollow structures enable their ideal drug delivery capabilities by improving drug aggregation in targeted sites and maintaining plasma concentrations at the optimal therapeutic ranges. This review begins with an in-depth explanation of the interactions and release mechanisms of hollow structure-based DDS, including diffusion, assembly, solvent activation, and chemical control, all of which are of great significance for the design of smart drug carriers. Next, recent advances in external microenvironmentresponsive drug delivery systems are introduced, based on various chemical signals and external field assists. Focusing on the unique view of intra-carrier variability, the strategies for regulating the internal environment are then highlighted, including pH regulation, temperature regulation, and mechanical force regulation. Finally, this review discusses possible challenges and prospects for hollow structure-based, particularly hollow multishelled structures intelligence-responsive drug delivery platforms, providing valuable strategies for the development of the next generation of responsive DDS.

show abstract

Engineered Platelets for Cancer Therapy

Zhang,

Li,

et al. 2024

Aggregate

View full text Add to dashboard Cite

While nanomedicine research shows a great progress in the treatment of cancer, it still faces challenges of tumor recurrence and metastasis. Numerous studies have demonstrated intricate crosstalk between platelets and tumor cells. The re‐education of platelets by tumor cells enables these platelets to provide critical assistance for tumor proliferation, recurrence, and metastasis. Engineered platelets have shown promising potential in the treatment of tumors, postoperative tumor recurrence, and tumor metastasis. Different engineering technologies such as surface modification, gene editing, membrane coating, and loading into hydrogels can produce multifunctional and customized engineered platelets. These engineered platelets inherit the key properties of platelets, including long blood circulation, tumor targeting, and thrombus targeting, and can be stimulated to generate derivatized particles. In this review, we elucidate the critical role of platelets in the complex processes of tumorigenesis and tumor progression and summarize the emerging paradigm of engineered platelets in tumor therapy. The purpose of this review is to comprehensively explore the potential value of engineered platelets toward the clinical treatment of cancer, providing a valuable reference for the further development of engineered platelets and their broader applications in the field of cancer therapy.

show abstract

Glycoprotein Ib-regulated micro platelet ghost for biosafe distribution and photothermal oncotherapy

Cited by 15 publications

References 47 publications

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

Biomimetic Nanoparticle-Mediated Target Delivery of Hypoxia-Responsive Plasmid of Angiotensin-Converting Enzyme 2 to Reverse Hypoxic Pulmonary Hypertension

Response and Regulation of the Microenvironment Based on Hollow Structured Drug Delivery Systems

Engineered Platelets for Cancer Therapy

Contact Info

Product

Resources

About